Skip to main content
. 2010 Feb 14;16(6):673–682. doi: 10.3748/wjg.v16.i6.673

Table 1.

Progression-free and overall survival analyses from the ECOG 6201 trial[11]

Parameter PFS
OS
Median (mo) Log-rank P Median (mo) Log-rank P
All eligible patients (n = 824) 2.9 5.6
Gem (n = 275) 2.6 4.9
FDR Gem (n = 277) 3.5 0.09 6.2 0.15
GemOx (n = 272) 2.7 5.7

PFS: Progression-free survival; OS: Overall survival; ECOG: Eastern Cooperative Oncology Group; Gem: Gemcitabine; GemOx: Gem and oxaliplatin.